Last reviewed · How we verify
NCT06729580
Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.
NA trial testing Behavioural Activation in Treatment Resistant Depression (TRD) in 118 participants. Completed in 30 October 2023.
30 October 2023
Quick facts
| Lead sponsor | McGill University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 118 |
| Start date | 5 January 2022 |
| Primary completion | 30 October 2023 |
| Estimated completion | 30 October 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Behavioural Activation
Conditions studied
- Treatment Resistant Depression (TRD) — all drugs for Treatment Resistant Depression (TRD) →
Sponsor
McGill University
Who can join
Eligibility, any sex, with Treatment Resistant Depression (TRD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is the most common diagnosis made for individuals seeking treatment for depression. Although a wide range of treatments have been developed for the treatment of MDD, a significant proportion of patients fail to respond. This study examined the effectiveness of a 10-week behavioural activation intervention for individuals with treatment-resistant depression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06729580
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Behavioural Activation
Trials testing the same drug.
- NCT05273983 — Pilot Study of a Brief Behavioural Activation Intervention for Depressed Patients in Primary Care · NA · terminated
- NCT05627154 — Combined Antidepressant and Behavioural Intervention · NA · completed
- NCT04317859 — Behavioural Activation Therapy for Bipolar Disorder · NA · unknown
- NCT03935529 — Behavioural Activation for Low Mood in Multiple Sclerosis · NA · completed
- NCT03661580 — BA Trial for Co-Occurring Depression and Substance Use · NA · completed
Other recruiting trials for Treatment Resistant Depression (TRD)
Currently open trials in the same condition.
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT06773949 — Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression · NA · recruiting
- NCT07264452 — Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst St · NA · recruiting
- NCT06682299 — Maintenance TMS in Treatment Resistant Depression · NA · recruiting
- NCT06668571 — Intravenous Ketamine for Treatment-Resistant Depression · Phase 2 · recruiting
Other McGill University trials
Trials by the same sponsor.
- NCT07178535 — Feasibility of Real-Time Visual Feedback in Augmented Reality to Reduce Gait Asymmetry Post-Stroke · NA · not yet recruiting
- NCT07445841 — Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training · NA · recruiting
- NCT07447830 — The Pain Reduction Using Immersive Virtual Reality During Wound Care Evaluation Study at Maimonides (PRISM) - Pilot Stud · NA · recruiting
- NCT07497425 — Neuroimmune Responses to Exercise in Chronic Back Pain · NA · recruiting
- NCT06994559 — Music as an Adjunct to Ketamine Therapy for Chronic Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06729580 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McGill University
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06729580.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing